- The P-III EXCEED study involves assessing Cosentyx (300mg) vs Humira (adalimumab, 40 mg) in 800+ biologic-naïve patients with PsA for 52wks.
- The P-III EXCEED results: Cosentyx narrowly missed statistical significance for superiority in ACR 20 but showed significant advantages in PsA specific endpoints, observed in a pre-specified sensitivity analysis, no new safety signals were observed
- Cosentyx is a mAb, selectively targeting IL-17A and is indicated to treat mod. to sev. plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy, for patients with active psoriatic arthritis and active ankylosing spondylitis
Click here to read full press release/ article | Ref: Novartis | Image: Money Control